Sign In
Buy EXAS
$104.91
+0 (+0%)
At Close: Jun 03, 2026
Is Exact Sciences or Editas Medicine the Better Growth Stock to Own in 2023?
11:00am, Thursday, 16'th Feb 2023
Which of these rebounding biotech stocks is the better buy right now?
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
03:00pm, Wednesday, 15'th Feb 2023 Zacks Investment Research
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exact Sciences Corporation: Fully Priced After Big Rally
12:22pm, Wednesday, 15'th Feb 2023
Today, we zero in on Exact Sciences Corporation, best known for its "best of breed" non-invasive stool-based DNA screening test called Cologuard. Exact Sciences stock has soared 35% so far in 2023 tha
Exact Sciences (EXAS) Gains As Market Dips: What You Should Know
11:00pm, Tuesday, 14'th Feb 2023 Zacks Investment Research
Exact Sciences (EXAS) closed at $65.52 in the latest trading session, marking a +0.17% move from the prior day.
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
03:00pm, Tuesday, 14'th Feb 2023 Zacks Investment Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMN Healthcare (AMN) to Post Q4 Earnings: What's in the Cards?
02:27pm, Monday, 13'th Feb 2023 Zacks Investment Research
AMN Healthcare's (AMN) fourth-quarter results are likely to reflect soft demand across the majority of its segments.
The Latest Analyst Ratings for Exact Sciences
03:00pm, Friday, 10'th Feb 2023 Benzinga
Analysts have provided the following ratings for Exact Sciences (NASDAQ:EXAS) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
2
2
0
0
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023
03:00pm, Friday, 10'th Feb 2023 Benzinga
Upgrades
According to SVB Leerink, the prior rating for AbbVie Inc (NYSE:ABBV) was changed from Underperform to Market Perform. In the fourth quarter, AbbVie showed an EPS of $3.60, compared to $3.08
Insulet (PODD) to Report Q4 Earnings: What's in the Cards?
02:26pm, Friday, 10'th Feb 2023 Zacks Investment Research
In Drug Delivery, Insulet (PODD) is expected to have faced higher manufacturing costs in Q4.
Ecolab (ECL) to Report Q4 Earnings: What's in the Offing?
02:36pm, Thursday, 09'th Feb 2023 Zacks Investment Research
Ecolab's (ECL) fourth-quarter results are likely to reflect continued strength in its Global Industrial segment.
Exact Sciences (EXAS) Stock Moves -1.09%: What You Should Know
11:00pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Exact Sciences (EXAS) closed the most recent trading day at $67.82, moving -1.09% from the previous trading session.
Exact Sciences (EXAS) Recently Broke Out Above the 20-Day Moving Average
02:35pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
3 Growth Stocks That Are Off to Hot Starts in 2023
12:45pm, Wednesday, 08'th Feb 2023 The Motley Fool
Are these stocks still good buys right now?
3 MedTech Stocks Likely to Beat Estimates This Earnings Season
12:42pm, Wednesday, 08'th Feb 2023 Zacks Investment Research
MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EXAS, MDT and IART are poised ahead of their earnings releases.
Exact Sciences (EXAS) Recently Broke Out Above the 20-Day Moving Average
11:18am, Wednesday, 08'th Feb 2023
Should investors be excited or worried when a stock crosses above the 20-day simple moving average?
